Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery
Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to assess the efficacy and safety of cell therapy with modified leukocyte cells from the participant himself/herself versus placebo in patients who develop Acute Kidney Injury (AKI) within the first 48 hours after cardiac surgery.
The main questions it aims to answer are:
* Does cell therapy reduce the recovery time of kidney function?
* What medical problems do participants have when receiving cell therapy?
Researchers will compare cell therapy with a placebo (a look-alike substance that contains no drug) to see if cell therapy works to treat AKI. The safety of cell therapy with leukocyte cells will also be studied.